

Dry Powder Inhalation

Drugs, Devices and Delivery Therapeutics



Greystone

associates

Greystone Associates

98 Route 101A • Suite 17

Amherst, NH 03031

603-595-4340 • fax 603-804-0466

New device designs are creating new therapeutic opportunities for dry powder drug formulations

Advances in particle engineering have led to enhanced particle size uniformity, optimized surface properties and sustained-release formulations

Design innovations such as microprocessor-based inhalers and dual chamber combination drug inhalers are on the leading edge of a trend toward feature-enhanced, user-friendly inhaler products

DPI will be a primary beneficiary of the trend toward therapeutically active biologics and bioengineered macromolecules for the treatment of a wide range of conditions.

Greystone Associates is pleased to announce the publication of a new market study. **Dry Powder Inhalation: *Drugs, Devices and Delivery Therapeutics*** is a comprehensive evaluation and analysis of the technology, devices, therapies and participants in this evolving and highly fluid segment of the pharmaceutical industry.

Published in May (2008), the study is designed to provide drug companies, device developers, formulators, and supply chain participants with a detailed understanding of the economics, technologies, products, and potential for pulmonary delivery of therapeutic substances via dry powder formulations. Provider organization business managers, healthcare administrators and investors will also benefit from this publication.

DPI and the Potential of Pulmonary Drug Delivery

The convergence of socioeconomic and technology factors – the growing emphasis on drug self-administration for chronic conditions, the expected acceleration in protein- and peptide-based therapeutics, the availability of innovative inhaler device designs - is driving interest in pulmonary drug delivery technology and devices as an alternative to oral and parenteral routes of administration. While several approaches for delivering active substances to, and systematically via, the lungs compete in this space, recent advances and investment in powder formulations, particle engineering, and device architecture have positioned dry powder inhalation (DPI) as a formidable challenger to more established pulmonary methods such as metered dose inhalers and nebulizers.

The importance of inhalation devices in drug delivery has traditionally derived from their ability to deliver pharmaceuticals to the upper lung and respiratory system for localized treatment of pulmonary diseases such as asthma and emphysema. While this remains the most attractive near-term market for DPI, the systemic delivery of both small and large molecule biologics and engineered macromolecules for the treatment of a range of pathologies represents significant long-term potential for dry powder pulmonary delivery systems.

Table of Contents

(abridged)

Executive Summary

Inhaled Drug Delivery Market Dynamics

Portrait of an Evolving Market
Established Therapeutic Targets
Emerging Therapies
Demographics and Growth
Competing Technologies
Market Drivers
Factors Limiting Growth

Dry Powder Inhalation Technology

Drug Formulations
 Dry Powder Particle Technology
 Particle/Powder Engineering
 Dry Powder Formulations
 Dry Powder Processing
 Dry Powder Packaging
 Emerging Formulations
Dry Powder Inhalers
 DPI Device Characteristics
 DPI Design Parameter
Emerging DPI Technologies

DPI Devices

Commercial Devices
Development-Stage Devices
Device Design Factors
Device Performance Factors

DPI Drug Delivery Therapeutics

Pulmonary Medicine
 Asthma
 COPD
Systemic Therapeutics
 Cystic Fibrosis
 Diabetes
 Hormone Therapy/Replacement
 Influenza
 Narcotic Analgesics
 Neurology
 Vaccines
 Other Potential Therapies
OTC Applications of DPI

Market Factors

FDA Regulations
Device Packaging
DPI Testing
Design Partnerships

Dry Powder Inhalation - Company Profiles

Market Data

The study presents qualitative and quantitative data and information on key market measures and benchmarks:

- Pulmonary Drug Delivery Market Segments and AGR
- Market Dynamics and Sensitivities
- Inhaled Drug Economic Factors
- DPI Technology Market Potential
- DPI Device Industry Structure
- DPI Design Parameters
- Third-party Stakeholders
- Market Participant Profiles
- Device-Pharma Alliance Activity and Deal Structure
- Competitive Risks
- Proprietary Technology
- Self-Medication User Issues
- Technology Risk Factors
- Regulatory Risk Factors

Forecasts and projections cover the period from 2008 to 2011.

Methodology

Research methodology is based on primary research in the form of in-depth interviews with key market participants, technology developers, supply chain participants, industry experts, and market influencers, a list that includes regulatory officials, industry trade groups, and standards organizations.

Primary data is evaluated and normalized against secondary sources including trade journal articles, technical literature, industry publications, company data sheets and published information, and statistical data from government agencies and trade associations.

Forecasts and projections of market demand and future market activity are derived using standard modeling and statistical techniques.

Feature Summary

- Analyzes and evaluates Dry Powder Inhalation and competing drug delivery technologies and assesses the market potential for existing and probable future products
- Examines Dry Powder Inhaler design issues and evolving market factors
- Provides detailed status of Dry Powder Inhalers currently in development
- Forecasts the impact of DPI technology and devices on drug delivery markets and projects probable future developments
- Profiles Dry Powder Inhalation market participants, their technology, product development activity, and business strategies
- Evaluates the impact of economic, technology, and regulatory factors on DPI devices, companies, and therapies

Report Format and Availability

This report is available in hard copy or electronic format. A site license for a single physical location and a global license are also available. Publication is scheduled for the first half of May, with availability to subscribers on or before May 15th.

About Greystone Associates

Greystone Associates is a medical technology consulting firm focused on medical market strategies, product commercialization, venture development, and market research. We assist medical market participants in achieving their business objectives through the creation of detailed business development strategies, product commercialization programs, and comprehensive market and technology research and analysis.

Our market research publications are designed, researched and written to provide timely and insightful information and data on focused market segments, with the aim of providing market participants with the essential knowledge necessary to refine and execute their marketing plans and achieve their financial targets.

Ordering Information

Orders may be placed via postal mail, e-mail or fax. Orders not accompanied by a purchase order must contain a telephone number for verification, and clearly indicate the physical shipping address. Orders which are not prepaid must indicate the billing address. There is no charge for handling and shipping for destination addresses within the continental US.

Payment

We accept the following forms of payment:

Company Check: Please make checks payable to 'Greystone Associates'

Credit Cards: We accept MasterCard, Visa and American Express




Orders Outside the U.S.

Orders must be prepaid via credit card, company check in US funds and drawn on a US bank, or wire transfer. There is a \$50 per copy shipping and handling charge for international shipments.

Wire Transfers: Bank of New Hampshire
300 Franklin Street
Manchester, NH 03103
(Call for Account Information)

Dry Powder Inhalation

Select	Format	Price (U.S. funds)	Total
<input type="checkbox"/>	Electronic	\$1,850.00	
<input type="checkbox"/>	Site License	\$2,850.00	
<input type="checkbox"/>	Global License	\$4,500.00	
Total Payment (U.S. funds)			

Method of Payment: Company Check    Wire Transfer (International)

Card Number: _____ Name on Card _____

Expiration Date: _____ Signature _____

Billing Information	Shipping Information
Name:	<input type="checkbox"/> Click here if same as Billing Information Name:
Title:	Title:
Company:	Company:
Street Address:	Street Address:
City,State/Province:	City,State/Province:
Country/Postal Code:	Country/Postal Code:
Phone:	Phone:
Fax:	Fax:
Email:	Email: